Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 333

The DOI matches its Crossref record; 361 of the 361 references it cites were found in a registry or an index.

Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas

Open access
Jolly, Mohit Kumar, Somarelli, Jason A., Sheth, Maya, Biddle, Adrian, Tripathi, Satyendra C., Armstrong, Andrew J., Hanash, Samir M., Bapat, Sharmila A., Rangarajan, Annapoorni, Levine, Herbert·2019·Pharmacology & Therapeutics

Abstract

ABSTRACT Cancer metastasis and therapy resistance are the major unsolved clinical challenges, and account for nearly all cancer‐related deaths. Both metastasis and therapy resistance are fueled by epithelial plasticity, the reversible phenotypic transitions between epithelial and mesenchymal phenotypes, including epithelial‐mesenchymal transition (EMT) and mesenchymal‐epithelial transition (MET). EMT and MET have been largely considered as binary processes, where cells detach from the primary tumor as individual units with many, if not all, traits of a mesenchymal cell (EMT) and then convert back to being epithelial (MET). However, recent studies have demonstrated that cells can metastasize in ways alternative to traditional EMT paradigm; for example, they can detach as clusters, and/or occupy one or more stable hybrid epithelial/mesenchymal (E/M) phenotypes that can be the end point of a transition. Such hybrid E/M cells can integrate various epithelial and mesenchymal traits and markers, facilitating collective cell migration. Furthermore, these hybrid E/M cells may possess higher tumor‐initiation and metastatic potential as compared to cells on either end of the EMT spectrum. Here, we review in silico, in vitro, in vivo and clinical evidence for the existence of one or more hybrid E/M phenotype(s) in multiple carcinomas, and discuss their implications in tumor‐initiation, tumor relapse, therapy resistance, and metastasis. Together, these studies drive the emerging notion that cells in a hybrid E/M phenotype may occupy ‘metastatic sweet spot’ in multiple subtypes of carcinomas, and pathways linked to this (these) hybrid E/M state(s) may be relevant as prognostic biomarkers as well as a promising therapeutic targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2018.09.007

Cites

361 of 361 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 361 references

Cited by

See all 333

Metadata

Authors
Jolly, M. K., Somarelli, J. A., Sheth, M., Biddle, A., Tripathi, S. C., Armstrong, A. J., Hanash, S. M., Bapat, S. A., Rangarajan, A., & Levine, H.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2019-02
Volume
194
Pages
161-184
ISSN
0163-7258 (ISSN-L)
OpenAlex
W2894407493
Cited by
333
References
361
FWCI
12.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. https://app.cochat.ai/papers/10.1016/j.pharmthera.2018.09.007
The paper
Jolly, M. K., Somarelli, J. A., Sheth, M., Biddle, A., Tripathi, S. C., Armstrong, A. J., Hanash, S. M., Bapat, S. A., Rangarajan, A., & Levine, H. (2019). Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2018.09.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.